Conferences

Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.

Major cardiology associations joined forces to define and standardize what exactly constitutes a heart attack, differentiating between myocardial infarction (MI) and “myocardial injury” while offering guidance on how to incorporate emerging imaging techniques and high-sensitivity troponin assays.

Combining oral anticoagulants with antiplatelet therapy in atrial fibrillation (AFib) patients could be more than just overkill, University of Edinburgh researchers reported at the European Society of Cardiology’s annual meeting this month. It could be dangerous, increasing the risk for all-cause death, stroke and major bleeding events in those without an indication for dual treatment.

Despite its relative rarity in clinical practice, the Ross procedure provides a survival benefit over mechanical aortic valve replacement in young and middle-aged patients, suggests a meta-analysis published in JAMA Cardiology and presented at the European Society of Cardiology (ESC) Congress in Munich.

The addition of perivascular fat attenuation to routine coronary computed tomography angiography (CTA) improves risk stratification in heart patients, according to research presented at the European Society of Cardiology (ESC)’s annual symposium in Munich, surpassing current prognostic models to re-classify and predict cardiac deaths with more accuracy.

Patients with stable chest pain who were evaluated with coronary CT angiography (CTA) were significantly less likely to experience a heart attack or die from coronary heart disease (CHD) within five years compared to individuals who received standard testing, researchers reported in the New England Journal of Medicine.

The British Heart Foundation announced at this year’s ESC (European Society of Cardiology) Congress it’s launching the Big Beat Challenge, a research award that will throw £30 million—nearly $40 million—behind an innovation that could change the future of cardiovascular medicine.

Though it’s used routinely to discourage repeat cardiovascular disease (CVD) events, a daily dose of aspirin is unlikely to prevent a first-time heart attack, according to research presented this week in Munich.

For patients hospitalized with an acute illness, prescribing rivaroxaban for 45 days after discharge doesn’t significantly reduce the risk of venous thromboembolism (VTE) or VTE-related death, according to research presented at the European Society of Cardiology Congress and published online in the New England Journal of Medicine.

For patients with acute myocardial infarction (MI) complicated by cardiogenic shock, stenting only the culprit lesion showed a trend toward improved one-year survival when compared to multivessel PCI, according to the latest results of the CULPRIT-SHOCK trial presented at the European Society of Cardiology Congress in Munich.

More than 40 percent of patients with atrial fibrillation (AFib) but no record of stroke or transient ischemic attack have previously unknown, “silent” brain damage, according to research presented this week at the European Society of Cardiology Congress (ESC) in Munich. The findings might explain why those with AFib also face an increased risk of cognitive dysfunction and dementia.

Numerous, deep forehead wrinkles could be a visual cue that a patient is more at risk for cardiovascular disease (CVD), according to research presented Aug. 26 at the European Society of Cardiology (ESC) Congress in Munich.